Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage an ...More

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market. ...Less

The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla ...More

The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at 26% during the quarter. ...Less

Cipla Q2 Results: Revenue from operations increased 6% year-on-year to Rs 7,051 crore in July-September 2 ...More

Cipla Q2 Results: Revenue from operations increased 6% year-on-year to Rs 7,051 crore in July-September 2024, up from Rs 6,678 crore in the same period last year. The company reported a 12% year-on-year EBITDA growth to Rs 1,886 crore in Q2. The One India business grew 5% YoY, with the Branded Prescription segment continuing to outperform the market in major chronic therapies. ...Less

Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful l ...More

Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the immunomodulatory drug Revlimid and continued market share expansion of Lanreotide used for the treatment of growth hormonal disorders. ...Less

Cipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 wi ...More

Cipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across branded prescription, trade generics and consumer health verticals ...Less

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenu ...More

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company saw strong performance in its India and North America businesses, with key products like Foracort and Albuterol leading. ...Less

Cipla's consolidated margins came in at 22.3% against the Street expectations of 22.1%. On a YoY basis, t ...More

Cipla's consolidated margins came in at 22.3% against the Street expectations of 22.1%. On a YoY basis, the margin improved by 10 basis points from 22.2% in the year-ago quarter. ...Less

The company had posted a net profit of Rs 253.34 for the same period of previous fiscal, Cipla Ltd said i ...More

The company had posted a net profit of Rs 253.34 for the same period of previous fiscal, Cipla Ltd said in a filing to BSE. ...Less

The company had reported Rs 422.39 crore profit in the same quarter last year. ...More

The company had reported Rs 422.39 crore profit in the same quarter last year. ...Less

Brokerage firm Sharekhan expects domestic loan growth of SBI to improve. ...More

Brokerage firm Sharekhan expects domestic loan growth of SBI to improve. ...Less

Ebitda increased 21 per cent to Rs 909 crore in the September quarter. ...More

Ebitda increased 21 per cent to Rs 909 crore in the September quarter. ...Less

Kotak Institutional Equities expects Cipla to report a 14.1 per cent rise in net profit, while net sales ...More

Kotak Institutional Equities expects Cipla to report a 14.1 per cent rise in net profit, while net sales may have increased 6 per cent from a year ago. ...Less

ICICI Securities said Cipla’s Q2FY22 result was above our estimates led by strong performance in India. H ...More

ICICI Securities said Cipla’s Q2FY22 result was above our estimates led by strong performance in India. However, it expects India growth to taper down in the coming quarters with declining contribution from COVID-19 portfolio and higher base. ...Less

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter comp ...More

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter compared to ₹2,139 crore in Q4FY25, while net interest income (NII) declined marginally by 0.41% sequentially from ₹6,051 crore in the same period. ...Less

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volu ...More

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volumes and flat revenues, while net profit could drop up to 5%. Cipla may report 3-6% revenue growth and a 4-5.7% rise in net profit. ...Less

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 n ...More

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 net profit to ₹565 crore despite a 12% rise in revenue. Sequentially, PAT dropped 50%, while segment performance showed mixed trends. ...Less

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, E ...More

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results. ...Less

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacte ...More

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth. ...Less